ArticleBMC neurology2025
An auxiliary diagnostic strategy for distinguishing Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: combining platelet-to-lymphocyte ratio and cerebrospinal fluid interleukin-8 levels.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Before Guillain-Barre Syndrome Is Attributed to a CMV Infection, the Diagnosis Must Be Confirmed and Other Causes Must Be Ruled Out.The Kaohsiung journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are immune-mediated neuropathies with overlapping clinical and electrophysiological features but distinct treatment strategies. This study investigated whether the platelet-to-lymphocyte ratio (PLR) and cerebrospinal fluid (CSF) interleukin-8 (IL-8) levels can serve as auxiliary biomarkers to aid in distinguishing CIDP from GBS.
methodsFor 65 patients with GBS, 38 with typical CIDP, and 65 healthy controls (HCs), clinical, serological, and CSF data were collected. Inflammatory markers were analyzed. Binary logistic regression was performed to identify risk factors and establish a prediction model. Receiver operating characteristic (ROC) curves were used to assess diagnostic performance.
resultsThe neutrophil-to-lymphocyte ratio (NLR), derived NLR, PLR, Systemic Inflammation Response Index, and Systemic Immune-Inflammation Index levels were significantly higher in the GBS than in the CIDP or HC groups (P < 0.05). The lymphocyte count was significantly higher in patients with CIDP than in those with GBS (P < 0.01). CSF IgG and IL-8 (both P < 0.001) were significantly higher in patients with GBS than in those with CIDP. ROC curve analysis showed that the area under the curve (AUC) of PLR was 0.746 and that of CSF IL-8 was 0.786. Combining PLR and CSF IL-8 levels improved the AUC to 0.827 (95% CI: 0.749-0.905), with a specificity of 0.973.
conclusionThe combination of PLR and CSF IL-8 levels may serve as a useful adjunct to conventional clinical and electrophysiological assessments for differentiating CIDP from GBS. These findings also contribute to a better understanding of the immunological differences between acute and chronic inflammatory neuropathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.